Cornerstone Pharmaceuticals

A Singular Focus on Cancer Metabolism

  • About
    • Overview
    • Leadership
    • Non-Executive Directors
    • Advisory Board Members
  • Cancer Metabolism
    • Overview
    • Our Approach
  • Platforms & Pipelines
    • Pipeline
    • AEMD/CPI-613
    • Emulsiphan/EmPAC
  • Clinical Trials
  • News & Media
    • Press Releases
    • News Coverage
    • Press Kit
    • Press Contacts
    • Scientific Papers and Abstracts
  • Careers
  • Contact
Home > About > Non-Executive Directors

Non-Executive Directors

  • Aaron Drillick
  • H. Gilbert Polinsky
  • A. Joseph Stern
  • Patrick S. Wilmerding
inner-1
  • News

December 12, 2011 Cornerstone Pharmaceuticals’ cancer metabolism inhibitor, CPI-613, showing promise in Phase I trial for acute myeloid leukemia

More View All

Copyright 2012 © Cornerstone Pharmaceuticals, Inc. All Rights Reserved.Privacy Policy | Terms & Conditions

  • Home
  • About Us
    • Overview
    • Leadership
    • Non-Executive Directors
    • Advisory Board Members
  • Cancer Metabolism
    • Overview
    • Our Approach
  • Platforms & Pipelines
    • Pipeline
    • AEMD/CPI-613
    • Emulsiphan/EmPAC
  • Clinical Trials
  • News & Media
    • Press Releases
    • News Coverage
    • Press Kit
    • Press Contacts
    • Scientific Papers and Abstracts
  • Careers
  • Contact

Cornerstone Pharmaceuticals Using its profound and proprietary understanding of cancer metabolism,
Cornerstone is dedicated to revolutionizing the way cancer is treated.

Website Design by Jackrabbit Design

Follow us on Twitter